Free Trial
→ Here’s Why Trump Won’t End The Iran War (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$6.06
-7.6%		$14.10
$4.37
▼
$31.35
$849.09M-0.382.61 million shs2.30 million shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$9.61
-2.2%		$11.39
$7.36
▼
$13.90
$874.48M0.471.80 million shs1.83 million shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$10.14
-2.6%		$13.83
$8.80
▼
$23.29
$885.96M1.082.02 million shs1.77 million shs
resTORbio, Inc. stock logo
TORC
resTORbio
$6.55
+1.9%		$12.16
$0.86
▼
$10.50
$238.77M2.431.15 million shs274,305 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-7.08%-5.34%-28.54%-77.23%+42.30%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-5.48%-6.65%-13.70%-13.24%-1.01%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-2.53%-4.93%-16.79%-47.85%-2.35%
resTORbio, Inc. stock logo
TORC
resTORbio
0.00%0.00%0.00%0.00%+577.21%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$6.06
-7.6%		$14.10
$4.37
▼
$31.35
$849.09M-0.382.61 million shs2.30 million shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$9.61
-2.2%		$11.39
$7.36
▼
$13.90
$874.48M0.471.80 million shs1.83 million shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$10.14
-2.6%		$13.83
$8.80
▼
$23.29
$885.96M1.082.02 million shs1.77 million shs
resTORbio, Inc. stock logo
TORC
resTORbio
$6.55
+1.9%		$12.16
$0.86
▼
$10.50
$238.77M2.431.15 million shs274,305 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-7.08%-5.34%-28.54%-77.23%+42.30%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-5.48%-6.65%-13.70%-13.24%-1.01%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-2.53%-4.93%-16.79%-47.85%-2.35%
resTORbio, Inc. stock logo
TORC
resTORbio
0.00%0.00%0.00%0.00%+577.21%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
2.86
Moderate Buy$33.27449.05% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.77
Moderate Buy$25.35163.82% Upside
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.43
Hold$28.50181.07% Upside
resTORbio, Inc. stock logo
TORC
resTORbio
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TORC, KURA, ALMS, and MLTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
10/14/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$24.00
10/14/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$24.00
10/14/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Outperform
10/5/2026
Alumis Inc. stock logo
ALMS
Alumis
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/5/2026
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/5/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/5/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$50.00
10/2/2026
Alumis Inc. stock logo
ALMS
Alumis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/1/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOverweight$30.00
9/16/2026
Alumis Inc. stock logo
ALMS
Alumis
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
$24.05M32.61N/AN/A$2.88 per share2.10
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$67.48M12.67N/AN/A$2.00 per share4.81
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$4.27 per shareN/A
resTORbio, Inc. stock logo
TORC
resTORbio
N/AN/AN/AN/A$2.24 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
-$243.32M-$3.86N/AN/AN/A-5,933.46%-93.15%-74.50%11/12/2026 (Estimated)
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$278.67M-$3.37N/AN/AN/A-384.30%-207.18%-45.17%11/3/2026 (Estimated)
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$227.32M-$3.84N/AN/AN/AN/A-82.53%-58.17%11/4/2026 (Estimated)
resTORbio, Inc. stock logo
TORC
resTORbio
-$82.74M-$2.41N/AN/AN/AN/A-78.12%-71.63%N/A

Latest TORC, KURA, ALMS, and MLTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.77N/AN/AN/AN/AN/A
11/3/2026Q3 2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.8144N/AN/AN/A$23.81 millionN/A
8/13/2026Q2 2026
Alumis Inc. stock logo
ALMS
Alumis
-$0.7670-$1.11-$0.3430-$1.11$3.65 million$1.66 million
8/12/2026Q2 2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.8773-$0.77+$0.1073-$0.77$20.16 million$20.87 million
8/10/2026Q2 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.9086-$0.84+$0.0686-$0.84N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
resTORbio, Inc. stock logo
TORC
resTORbio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
6.74
6.74
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.12
4.73
4.71
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.23
12.56
12.56
resTORbio, Inc. stock logo
TORC
resTORbio
N/A
20.69
20.69

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%
resTORbio, Inc. stock logo
TORC
resTORbio
46.19%

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
33.70%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
7.60%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
10.40%
resTORbio, Inc. stock logo
TORC
resTORbio
11.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
239129.43 million85.82 millionN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
26088.96 million82.20 millionOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
13085.11 million76.26 millionOptionable
resTORbio, Inc. stock logo
TORC
resTORbio
N/A36.45 millionN/ANot Optionable

Recent News About These Companies

TinOne Announces Convertible Debenture Interest Payment
February 19, 2026  |  newsfilecorp.comN
TinOne Closes $300,000 Private Placement Financing
September 2, 2025  |  newsfilecorp.comN
TinOne Upsizes Private Placement
August 19, 2025  |  newsfilecorp.comN
TinOne Announces Re-Pricing of Private Placement
July 30, 2025  |  newsfilecorp.comN
John Flynn
April 24, 2024  |  fleetowner.comF
Adicet Bio Inc (ACET)
January 30, 2024  |  investing.comhttps://www.investing.com/equities/restorbio
Targeting the biology of aging with mTOR inhibitors - Nature.com
May 4, 2023  |  news.google.comN
PARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid ... - OncLive
March 17, 2023  |  news.google.comN
Michelle Chaka Joins Torc as Senior Vice President, Safety and Regulatory
February 24, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/michelle-chaka-joins-torc-senior-150000620.html
Torc names regulatory, safety SVP
February 24, 2023  |  virginiabusiness.comV
Global AI in Life Extension Market Poised for Growth Amidst Rising Demand for Prolonging Life (2022 - 2030) - openPR
February 8, 2023  |  news.google.comN
Phenotypic Presentations and the Management of Moderate to ... - Healio
January 31, 2023  |  news.google.comN
Aerovate Therapeutics Appoints Donald Santel To Its Board of ... - Marketscreener.com
January 23, 2023  |  news.google.comN
Aerovate Therapeutics Appoints Donald Santel To Its Board of ... - GlobeNewswire
January 23, 2023  |  news.google.comN
TinOne Resources Inc. (TORC.V)
January 10, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/quote/TORC.V/history/
resTORbio IPO on Deck, Less than a Year After Licensing Clinical ... - Equities News
December 16, 2022  |  news.google.comN
resTORbio Shows Positive Phase 2b Data in Respiratory Tract Infections - Equities News
December 12, 2022  |  news.google.comN
Brian Kennedy – validating aging interventions and why rapamycin is the gold standard - Longevity.Technology
November 3, 2022  |  news.google.comN
TORC Investments, LLC
October 6, 2022  |  gwinnettdailypost.comG
Celebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - Forbes
September 19, 2022  |  forbes.comhttps://www.forbes.com/sites/alexzhavoronkov/2022/09/19/celebrity-strategy-consultant-predicts-what-will-be-the-most-impactful-area-in-the-pharmaceutical-industry/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alumis stock logo

Alumis NASDAQ:ALMS

$6.06 -0.50 (-7.62%)
Closing price 04:00 PM Eastern
Extended Trading
$6.07 +0.01 (+0.10%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$9.61 -0.22 (-2.24%)
Closing price 04:00 PM Eastern
Extended Trading
$9.62 +0.01 (+0.05%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$10.14 -0.27 (-2.59%)
Closing price 04:00 PM Eastern
Extended Trading
$10.14 +0.00 (+0.05%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

resTORbio stock logo

resTORbio NASDAQ:TORC

Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas